News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
Views & Analysis To you it's a document; to me it's my life Proactive and included patients can help clinical trial retention.
News Merrimack goes back to drawing board with $1bn Ipsen sell-of... Merrimack sells off Onivyde and generic cancer drug
Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.